drugset / Trial / NCT01172964
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Genetically-modified neural stem cells (NSCs) that convert 5-fluorocytosine (5-FC) into the chemotherapy agent 5-FU (fluorouracil) at sites of tumor in the brain may be an effective treatment for glioma. PURPOSE: This clinical trial studies genetically-modified NSCs and 5-FC in patients undergoing surgery for recurrent high-grade gliomas.
Timeline
- Start
- 2010-08
- Primary completion
- 2015-02-11
- Completion
- 2015-02-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | E. coli CD-expressing genetically modified neural stem cells | Cell therapy | — | Other |
| Subject | Flucytosine | Small molecule | — | Oral |